[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344796-105":59,"doc-detail-344796-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","analysis-of-cacybpsip-erk12-and-p38-expression-in-low-and-high-grade-papillary-urothelial-carcinoma","Analysis of CacyBP/SIP, ERK1/2, and p38 Expression in Low-and High-Grade Papillary Urothelial Carcinoma","","Background: Papillary urothelial carcinoma is a common urinary tract malignancy, divided into low-grade and high-grade forms whose aggressiveness depends on stage and grade. CacyBP/SIP and MAP kinases regulate signaling pathways linked to cell survival or death. This study assessed CacyBP/SIP, ERK1/2, and p38 expression in low- and high-grade papillary urothelial carcinoma using immunohistochemistry and qRT-PCR. Materials and Methods: Tumor tissues from 20 high-grade and 20 low-grade patients were compared with adjacent non-cancerous controls. Results: CacyBP/SIP showed strongest high-malignancy potential expression, mainly in nuclei; p38 was increased, while ERK1/2 was reduced versus controls. Conclusions: Findings indicate CacyBP/SIP may promote progression by modulating ERK1/2 and p38 kinase activity.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/analysis-of-cacybpsip-erk12-and-p38-expression-in-low-and-high-grade-papillary-urothelial-carcinoma/344796/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/analysis-of-cacybpsip-erk12-and-p38-expression-in-low-and-high-grade-papillary-urothelial-carcinoma/344796.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the study?","Question",{"text":112,"@type":113},"To assess the expression of CacyBP/SIP, ERK1/2, and p38 in low- and high-grade papillary urothelial carcinoma using immunohistochemical and molecular analyses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the tumor and control tissues selected?",{"text":117,"@type":113},"Tissue samples were obtained from 20 patients with high-grade urothelial carcinoma and 20 with low-grade urothelial carcinoma, with adjacent non-cancerous tissues used as comparative controls.",{"name":119,"@type":110,"acceptedAnswer":120},"What expression pattern differences were found between high-grade and low-grade tumors?",{"text":121,"@type":113},"CacyBP/SIP showed the strongest expression in tissues with high malignant potential, mainly in the nuclear compartment; p38 expression was elevated, while ERK1/2 expression was reduced compared with adjacent normal bladder tissues.",{"name":123,"@type":110,"acceptedAnswer":124},"What do the results suggest about CacyBP/SIP in cancer progression?",{"text":125,"@type":113},"CacyBP/SIP may play a critical role in urothelial carcinoma progression by modulating ERK1/2 and p38 kinase activity.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},344796,1791068868,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":46,"preview_page_count":19,"preview_urls":148},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nAnalysis of CacyBP/SIP, ERK1/2, and p38 Expression in Low-and High-Grade Papillary Urothelial Carcinoma  \nNatalia Domian1 | Grzegorz Młynarczyk2 | Irena Kasacka1   \n1Department of Histology and Cytophysiology, Medical University of Białystok, Białystok, Poland | 2Department of Urology, Medical University of Białystok, Białystok, Poland  \nCorrespondence: Irena Kasacka ([kasacka@umb.edu.pl](kasacka@umb.edu.pl); [histologia.cytofizjologia@umb.edu.pl](histologia.cytofizjologia@umb.edu.pl))  \nReceived: 5 November 2025 | Revised: 30 January 2026 | Accepted: 4 February 2026  \nKeywords: bladder cancer | CacyBP/SIP | ERK1/2 | p38 | papillary urothelial carcinoma  \nABSTRACT  \nBackground: Papillary urothelial carcinoma (transitional cell carcinoma) is one of the most common malignant tumors of the urinary tract. Urothelial carcinomas are classified into muscle-invasive and non-muscle-invasive types. Among the latter, papillary urothelial carcinoma is further categorized into low-grade and high-grade forms. The aggressiveness of bladder cancer depends on the stage and grade of the disease. The CacyBP/SIP protein and MAP kinases play key roles in various cellular processes and signaling pathways that determine cell survival or death. This study aimed to assess the expression of CacyBP/SIP, ERK1/2, and p38 in low-and high-grade papillary urothelial carcinoma using immunohistochemical and molecular analyses. Materials and Methods: Tissue samples were obtained from 20 patients with high-grade urothelial carcinoma and 20 patients with low-grade urothelial carcinoma. Adjacent non-cancerous tissues served as comparative controls. Immunohistochemistry and qRT-PCR were used to evaluate the expression of CacyBP/SIP, ERK1/2, and p38 .  \nResults: The strongest expression of the CacyBP/SIP gene was observed in tumor tissues with high malignant potential, predominantly in the nuclear compartment. Similarly, p38 kinase expression was elevated, whereas ERK1/2 expression was reduced in bladder tumor tissues compared to adjacent normal bladder tissues.  \nConclusions: These findings suggest that CacyBP/SIP may play a critical role in urothelial carcinoma progression by modulating ERK1/2 and p38 kinase activity.  \n1 | Background  \nBladder cancer accounts for approximately 3% of all malignancies and is the second most common malignant tumor of the urinary system. It is responsible for 2.1% of cancer-related deaths, making it the 13th leading cause of cancer-related mortality worldwide. An increase in the incidence of bladder cancer has been observed in recent decades, particularly in industrialized countries [1–4] . The most frequently diagnosed type is urothelial carcinoma, which accounts for 90% of cases and originates from the transitional epithelium. Urothelial carcinomas are classified as muscle-invasive and non-muscle-invasive. Among the latter, papillary urothelial carcinoma is further categorized  \ninto low-grade (LG-UC) and high-grade (HG-UC) forms. The aggressiveness of bladder cancer depends on the stage and grade of the disease; high-grade (poorly differentiated) tumors have a greater potential for progression and metastasis compared to low-grade (well-differentiated) tumors [5–7] .  \nCacyBP/SIP is a multifunctional protein containing multiple domains. It is expressed in a variety of mammalian cells and tissues. It has been shown that the CacyBP/SIP protein in the cytoplasmic compartment, and under the influence of various factors, can translocate to the cell nucleus or the perinuclear area. In recent years, scientists have investigated the involvement of CacyBP/SIP in the occurrence and development of  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2","cbCaidrzqkfljNLj","https://ap.wps.com/l/cbCaidrzqkfljNLj","pdf",1238683,"English","# Background\n## Bladder cancer classification and grade\n## Roles of CacyBP/SIP and MAP kinases (ERK1/2, p38)\n# Materials and Methods\n## Patient tissue samples and controls\n## Immunohistochemistry and qRT-PCR\n# Results\n# Conclusions","[{\"question\":\"What was the purpose of the study?\",\"answer\":\"To assess the expression of CacyBP/SIP, ERK1/2, and p38 in low- and high-grade papillary urothelial carcinoma using immunohistochemical and molecular analyses.\"},{\"question\":\"How were the tumor and control tissues selected?\",\"answer\":\"Tissue samples were obtained from 20 patients with high-grade urothelial carcinoma and 20 with low-grade urothelial carcinoma, with adjacent non-cancerous tissues used as comparative controls.\"},{\"question\":\"What expression pattern differences were found between high-grade and low-grade tumors?\",\"answer\":\"CacyBP/SIP showed the strongest expression in tissues with high malignant potential, mainly in the nuclear compartment; p38 expression was elevated, while ERK1/2 expression was reduced compared with adjacent normal bladder tissues.\"},{\"question\":\"What do the results suggest about CacyBP/SIP in cancer progression?\",\"answer\":\"CacyBP/SIP may play a critical role in urothelial carcinoma progression by modulating ERK1/2 and p38 kinase activity.\"}]","Analysis of CacyBP/SIP, ERK1/2, and p38 Expression in Low-and High-Grade Papillary Urothelial Carcinoma | PDF",1790055288,[149,153,157,161],{"page_no":8,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/064edbf0ade8536ff9846f4fc15eba8c.webp",983,1291,{"page_no":14,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d55eee24e4b540cc7749da9596822f9.webp",982,1290,{"page_no":81,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77cf402688cd052071632017a214eed3.webp",981,1289,{"page_no":19,"url":162,"width":163,"height":164},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b040899632322de3e72bab351030da30.webp",980,1287]